Literature DB >> 12212985

Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease.

R Polosa1.   

Abstract

Adenosine administration by inhalation elicits concentration-related bronchoconstriction in subjects with asthma and chronic obstructive pulmonary disease (COPD). The mechanisms of adenosine-induced bronchoconstriction appear to involve a selective interaction with activated mast cells with subsequent release of preformed and newly-formed mediators. Further evidence linking adenosine signalling to asthma and COPD comes from the finding that many cell types that play important roles in the exacerbation of these conditions express adenosine receptors and demonstrate relevant effects through stimulation of these receptors. Therefore, blockade of these receptors may be a valuable approach to the treatment of asthma and chronic obstructive pulmonary disease. Promising adenosine-receptor targets for novel therapeutics of asthma and chronic obstructive pulmonary disease have recently been identified in a number of inflammatory cell types, including mast cells, eosinophils, lymphocytes, neutrophils, and macrophages. The recent characterisation of the A2B receptors indicates the human lung mast cell as one of the most strategic cellular targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212985     DOI: 10.1183/09031936.02.01132002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control.

Authors:  G Tintinger; H C Steel; R Anderson
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 3.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 4.  Pharmacotherapy of asthma.

Authors:  Martin M Zdanowicz
Journal:  Am J Pharm Educ       Date:  2007-10-15       Impact factor: 2.047

Review 5.  Adenosine receptors and asthma.

Authors:  Constance N Wilson; Ahmed Nadeem; Domenico Spina; Rachel Brown; Clive P Page; S Jamal Mustafa
Journal:  Handb Exp Pharmacol       Date:  2009

Review 6.  The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders.

Authors:  Dietrich van Calker; Knut Biber
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

7.  Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist.

Authors:  Paul Eastwood; Cristina Esteve; Jacob González; Silvia Fonquerna; Josep Aiguadé; Inés Carranco; Teresa Doménech; Mònica Aparici; Montserrat Miralpeix; Joan Albertí; Mónica Córdoba; Raquel Fernández; Mercè Pont; Núria Godessart; Neus Prats; María Isabel Loza; María Isabel Cadavid; Arsenio Nueda; Bernat Vidal
Journal:  ACS Med Chem Lett       Date:  2010-12-20       Impact factor: 4.345

8.  Adenosine A(1) and prostaglandin E receptor 3 receptors mediate global airway contraction after local epithelial injury.

Authors:  Jian Zhou; Martha B Alvarez-Elizondo; Elliot Botvinick; Steven C George
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-06       Impact factor: 6.914

Review 9.  Adenosine receptors and asthma in humans.

Authors:  C N Wilson
Journal:  Br J Pharmacol       Date:  2008-10       Impact factor: 8.739

10.  Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor.

Authors:  S Mark Duffy; Glenn Cruse; Christopher E Brightling; Peter Bradding
Journal:  Eur J Immunol       Date:  2007-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.